Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Home/
      2. Media Center/
      3. Press releases /
      4. Innovative Medicine

      Innovative Medicine

      Innovative Medicine
      December 20, 2016

      Positive Results From First Phase III Studies of Investigational Two-Drug HIV Treatment Regimen

      Investigational Two-Drug Regimen of Rilpivirine and Dolutegravir Shows Efficacy As Maintenance Therapy in Patients Who Have Already Achieved Viral Suppression
      Learn more
      Innovative Medicine
      December 16, 2016

      Janssen Submits Application Seeking FDA Approval Of Stelara® (Ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis

      Learn more
      Innovative Medicine
      December 6, 2016

      Late-breaking Phase 2 Ibrutinib Study in Chronic Graft-Versus-Host-Disease (cGVHD) Showed Complete or Partial Response in Up to Two-Thirds of Steroid Dependent or Refractory Patients

      Learn more
      Innovative Medicine
      December 6, 2016

      New Analysis Shows People with Cancer Who Received XARELTO® (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment

      Learn more
      Innovative Medicine
      December 5, 2016

      New Ibrutinib (IMBRUVICA®) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkin’s Lymphoma

      Learn more
      Innovative Medicine
      December 5, 2016

      Daratumumab (DARZALEX®) Combination Therapy Showed Consistent Clinical Benefit for Previously-Treated Patients with Multiple Myeloma

      Learn more
      Innovative Medicine
      November 25, 2016

      Janssen Submits Application To Ema Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis

      Learn more
      Innovative Medicine
      November 21, 2016

      DARZALEX® (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy

      Learn more
      Global Health Equity
      November 21, 2016

      Johnson & Johnson Announces World Health Organization will Review Ebola Vaccine Regimen for Emergency Use Assessment and Listing (EUAL)

      Preparations also underway to initiate first-in-human study for multivalent vaccine regimen to combat Ebola, Sudan and Marburg viruses
      Learn more
      Load more